Xanthoma of Tendon – A Complete Patient‑Friendly Guide

Overview

Xanthoma of tendon (also called tendon xanthoma) is a benign, yellow‑orange deposit of lipid‑laden macrophages (foam cells) that forms within the substance of large tendons—most commonly the Achilles, extensor tendons of the hands, and the patellar tendon. These lesions are not cancerous, but they are a visible sign of an underlying disorder of lipid metabolism, especially familial hypercholesterolemia (FH).

• Who it affects: Primarily adults with genetically elevated low‑density lipoprotein (LDL) cholesterol. The condition can appear in children as early as 5–10 years old in severe FH families.
• Prevalence: Tendon xanthomas occur in up to 20 % of patients with heterozygous FH and >80 % of those with homozygous FH. In the general population, the prevalence is <0.5 % (Mayo Clinic, 2020).
• Gender: Slight male predominance (about 1.3 : 1), likely because men are more frequently screened for FH.

Symptoms

Most tendon xanthomas are painless and discovered incidentally, but they can cause discomfort or functional limitation when they enlarge.

Typical signs

• Yellow‑orange nodules or plaques on the tendon surface—often palpable as firm, rubbery masses.
• Location specific: Achilles tendon (posterior ankle), extensor tendons of the fingers (particularly the fourth and fifth), and the patellar tendon (just above the knee).
• Size variation: From a few millimeters to >2 cm in length; larger lesions may feel “lumpy”.

Associated symptoms

• Localized pain or tenderness when the tendon is strained (e.g., during running or climbing stairs).
• Reduced range of motion if the mass interferes with tendon gliding.
• Skin changes – occasional overlying skin thinning or small ulcerations if the lesion is traumatized.
• Systemic clues – many patients also have xanthelasma (eyelid plaques), corneal arcus, or premature atherosclerotic disease, pointing to an underlying lipid disorder.

Causes and Risk Factors

Underlying mechanisms

Tendon xanthomas develop when plasma LDL particles infiltrate the tendon matrix, become oxidized, and are taken up by resident macrophages. The macrophages transform into foam cells that accumulate cholesterol esters, giving the lesion its characteristic color.

Key causes

• Familial hypercholesterolemia (FH) – autosomal dominant mutations in the LDL‑R, APOB, or PCSK9 genes are responsible for >90 % of cases.
• Other dyslipidemias – severe hypertriglyceridemia, sitosterolemia, and cholestatic liver disease can also produce xanthomas, though tendinous involvement is less common.
• Secondary causes – prolonged use of certain medications (e.g., glucocorticoids, protease inhibitors) may raise LDL levels enough to trigger xanthoma formation in susceptible individuals.

Risk factors

• Genetic mutation for FH (heterozygous or homozygous).
• LDL‑cholesterol ≥190 mg/dL untreated.
• Family history of early‑onset coronary artery disease (<55 y men, <65 y women).
• Male sex (slightly higher prevalence).
• Smoking and sedentary lifestyle – accelerate atherosclerosis, indirectly increasing xanthoma risk.

Diagnosis

Clinical evaluation

• Detailed history focusing on lipid levels, family history of FH or premature heart disease, and any prior xanthomas elsewhere.
• Physical exam – inspection and palpation of tendons; note size, consistency, and symmetry.

Laboratory tests

• Lipid panel – fasting total cholesterol, LDL‑C, HDL‑C, triglycerides.
• Genetic testing for FH mutations (recommended when LDL‑C >190 mg/dL or when tendon xanthomas are present).

Imaging studies

• Ultrasound – readily available; shows hyperechoic thickening within the tendon, helps differentiate from cysts or tumors.
• MRI – provides excellent soft‑tissue contrast; useful for surgical planning or when the diagnosis is uncertain.
• CT scan – rarely needed, but can evaluate calcification within large lesions.

Biopsy

Rarely required because the appearance is characteristic. If performed, histology shows lipid‑laden macrophages (foam cells) within a collagenous matrix, stained positively with Oil‑Red O or Sudan IV.

Treatment Options

Tendon xanthomas themselves are not dangerous, but their presence signals high cardiovascular risk. Treatment therefore targets the underlying lipid disorder, with surgery reserved for symptomatic or cosmetically concerning lesions.

Medication

• Statins (e.g., rosuvastatin, atorvastatin) – first‑line; lower LDL‑C by 30–55 % and have been shown to reduce xanthoma size over years (Cleveland Clinic, 2022).
• Ezetimibe – adds ~15‑20 % further LDL reduction when combined with a statin.
• PCSK9 inhibitors (evolocumab, alirocumab) – for patients with FH who cannot reach target LDL‑C with statins/eze­timibe; can lower LDL‑C >60 % and may cause regression of xanthomas.
• Lomitapide & Mipomersen – oral and injectable agents approved for homozygous FH; substantial LDL‑C reductions, but limited by liver toxicity and cost.

Lifestyle modifications

• Diet: Plant‑sterol fortified foods, soluble fiber (oats, beans), and a Mediterranean‑style diet reduce LDL‑C by 5‑15 %.
• Exercise: At least 150 min of moderate aerobic activity per week improves lipid profile and cardiovascular fitness.
• Weight management: Maintaining a BMI <25 kg/m² helps lower LDL‑C and triglycerides.
• Smoking cessation – eliminates a major accelerator of atherosclerosis.

Surgical / Procedural options

• Excisional surgery – removal of the xanthoma mass, usually under regional anesthesia. Indicated for pain, functional limitation, or severe cosmetic concern.
• Laser ablation or cryotherapy – emerging minimally invasive techniques; limited data but can shrink small lesions.
• Recurrence – high if lipid levels remain uncontrolled; thus surgery must be paired with aggressive medical therapy.

Follow‑up care

Regular lipid panels every 3–6 months until targets are met, then annually. Imaging of the affected tendon (ultrasound) can be repeated every 1–2 years to monitor lesion size.

Living with Xanthoma of Tendon

Daily management tips

• Skin care: Keep the overlying skin clean and moisturized to avoid cracking or infection.
• Footwear: Use cushioned shoes with good arch support if the Achilles tendon is involved; avoid high‑impact activities that provoke pain.
• Self‑monitoring: Measure the longest dimension of the lesion with a ruler every few months; note any rapid growth.
• Medication adherence: Set daily alarms; use pill‑organizer boxes; discuss side‑effects promptly with your clinician.
• Family screening: First‑degree relatives should have lipid panels and possibly genetic testing, as FH is autosomal dominant.

Psychosocial considerations

Visible yellow plaques can be distressing. Support groups (e.g., FH Foundation) and counseling can improve quality of life. Cosmetic concerns may be addressed after lipid control is achieved.

Prevention

• Early detection of FH: Universal cholesterol screening at ages 9–11 and again at 17–21 (American Academy of Pediatrics recommendation) can identify affected children before xanthomas develop (CDC, 2023).
• Aggressive lipid lowering: Initiate statin therapy in children with heterozygous FH as early as 8–10 years old, per NHLBI guidelines.
• Healthy lifestyle from childhood: Balanced diet, regular activity, and avoidance of tobacco.
• Medication compliance: Maintaining target LDL‑C (<70 mg/dL for very high risk, <100 mg/dL for high risk) reduces the likelihood of new xanthoma formation.

Complications

• Cardiovascular disease: Tendon xanthomas are a strong predictor of premature coronary artery disease, peripheral arterial disease, and stroke. In FH cohorts, the presence of xanthomas triples the 10‑year risk of a major cardiac event (NIH, 2020).
• Tendon rupture: Large, infiltrative xanthomas can weaken tendon fibers, increasing the risk of spontaneous or trauma‑related rupture, especially in the Achilles.
• Infection: Overlying skin breakdown can lead to cellulitis; prompt treatment with antibiotics is essential.
• Functional limitation: Pain and reduced range of motion may impair walking, running, or grip strength, impacting daily activities.
• Psychological impact: Cosmetic disfigurement may cause anxiety and reduced self‑esteem.

When to Seek Emergency Care

---

References

1. Mayo Clinic. Tendon xanthoma. 2020. https://www.mayoclinic.org
2. Cleveland Clinic. Lipid Management & Tendon Xanthomas. 2022. https://my.clevelandclinic.org
3. CDC. Cholesterol Screening Guidelines. 2023. https://www.cdc.gov
4. NIH National Heart, Lung, and Blood Institute. 2020 FH Clinical Guidelines. https://www.nhlbi.nih.gov
5. World Health Organization. Cardiovascular disease risk charts. 2021. https://www.who.int
6. American Academy of Pediatrics. Lipid Screening Recommendations. 2023. https://pediatrics.aappublications.org